Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results
Eagle Pharmaceuticals, Inc. (EGRX)
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.eagleus.com
Company Research
Source: Business Wire
-- Q4 2019 net income was $0.07 per basic and diluted share and adjusted non-GAAP net income was $0.49 per basic and $0.48 per diluted share –-- FY 2019 net income was $1.04 per basic and $1.01 per diluted share and adjusted non-GAAP net income was $2.68 per basic and $2.61 per diluted share ---- Significant pipeline advancements position Eagle for five potential commercial launches over next three years ---- Company anticipates strong 2020 growth for total revenue and gross profit based on strength of marketed products, and assuming an on-time approval for RYANODEX® for exertional heat stroke and affirmation of orphan drug decision by the Appellate Court for BENDEKA® ---- Received final approval from the U.S. Food and Drug Administration (“FDA”) for PEMFEXY™ (pemetrexed for injection), for an initial entry of PEMFEXY on February 1, 2022, and a subsequent uncapped entry on April 1, 2022 ---- Resubmitted NDA for RYANODEX (dantrolene sodium for injectable suspension) for the treatment o
Show less
Read more
Impact Snapshot
Event Time:
EGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EGRX alerts
High impacting Eagle Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EGRX
News
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
EGRX
Sec Filings
- 12/10/24 - Form EFFECT
- 12/2/24 - Form 8-K
- 11/27/24 - Form RW
- EGRX's page on the SEC website